Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.57 |
| ▸ | DKK1 | O94907 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100516 | 0.84 | VCP (0.47) | MAPK8MAPK10CDK2 | |
| SCHEMBL5093306 | 0.83 | PKM (0.47) | IKBKB | |
| SCHEMBL5093927 | 0.81 | PIK3CA (0.52) | IKBKB | |
| SCHEMBL5093422 | 0.81 | MAPK8 (0.57) | IKBKBGSK3BMAPK8MAPK10JAK2 | |
| SCHEMBL5095126 | 0.81 | MKNK1 (0.51) | IKBKBGSK3BMAPK8MAPK10MRGPRX1 | |
| SCHEMBL5100580 | 0.79 | MEN1 (0.47) | IKBKBJAK2 | |
| SCHEMBL5100245 | 0.78 | ABL1 (0.58) | — | |
| SCHEMBL7844380 | 0.78 | MAPK8 (0.53) | IKBKBGSK3BMAPK8MAPK10JAK2 | |
| SCHEMBL5099513 | 0.77 | NISCH (0.42) | CDK2CDK1MTORSMG1CDK4 | |
| SCHEMBL5092325 | 0.76 | CSNK2A1 (0.45) | GSK3BCDK2CDK1MTORSMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | IKBKB 161/4885DKK1 818/4885GSK3B 1/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | IKBKB 161/4885DKK1 818/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.